image1 (1).png
Evaxion significantly expands vaccine development collaboration with MSD
26 sept. 2024 07h30 HE | Evaxion Biotech
Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on...
Anaveon_dark_blue_logo high res.jpg
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
29 mai 2024 02h00 HE | Anaveon
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
Proxygen Logo.jpg
Proxygen Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Molecular Glue Degraders
05 avr. 2023 07h00 HE | Proxygen
VIENNA, Austria, April 05, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research collaboration and license...
new logo.jpg
Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer
16 mars 2021 08h00 HE | Immutep Limited
New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA® (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC)HNSCC is one of the...
new logo.jpg
Immutep Expands Part B of TACTI-002 Study
05 mars 2021 08h00 HE | Immutep Limited
Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...
HealthEC_logo.jpg
Medical Society of Delaware Partners with HealthEC To Provide Population Health Platform to Nearly 900 Physicians
07 déc. 2017 09h37 HE | HealthEC
NEWARK, Del. and PISCATAWAY, N.J., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Medical Network Management Services of Delaware, LLC (MedNet), a wholly-owned subsidiary of the Medical Society of Delaware...